Search Clinical Trials
Sponsor Condition of Interest |
---|
Genomics, Environmental Factors and Social Determinants of Cardiovascular Disease in African-Americans...
National Human Genome Research Institute (NHGRI)
Heart Disease
Background:
The COVID-19 pandemic infected and killed African Americans at higher rates than other
Americans. Researchers want to understand why.
Objective:
This natural history study will look at how genetic, environmental, and social factors may
predict... expand
Background: The COVID-19 pandemic infected and killed African Americans at higher rates than other Americans. Researchers want to understand why. Objective: This natural history study will look at how genetic, environmental, and social factors may predict or affect COVID-19 in African Americans. Information from this study will be combined with data from the GENE-FORECAST study. Eligibility: African Americans who were previously enrolled in GENE-FORECAST. Design: The study includes a telephone interview and 1 visit to the NIH clinic. Participants may engage in either one or both of these activities. The telephone interview will last 20 minutes. Participants will talk about their experiences during the COVID-19 pandemic. The clinic visit will last up to 4 hours. Participants will have a physical exam. They will have blood and urine tests. They will be tested for COVID-19. A long swab will be inserted into a nostril to get a fluid sample from the back of the nose. They will have noninvasive tests of their blood vessels. One device used is a pen-like probe placed lightly on the wrist. Another is a rubber sleeve placed around a finger while a blood pressure cuff is used on the arm. Participants will have a test to measure the electrical activity in their heart. Stickers attached to wires will be placed on their chest, arms, and legs. Participants will answer more questions about COVID-19. They will talk about their health behavior. They will talk about their family's health and the neighborhood they live in. Other questions will ask how they feel, live, work, and play. Type: Observational Start Date: Feb 2023 |
RECOVER-AUTONOMIC: Platform Protocol, Appendix B (Ivabradine)
Kanecia Obie Zimmerman
Long COVID
Long Covid19
Long Covid-19
This study is a platform protocol designed to be flexible so that it is suitable for a wide
range of settings within health care systems and in community settings where it can be
integrated into COVID-19 programs and subsequent treatment plans.
This protocol is a prospective,... expand
This study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans. This protocol is a prospective, multi-center, multi-arm, randomized, controlled platform trial evaluating various interventions for use in the treatment of autonomic dysfunction symptoms, including cardiovascular complications and postural orthostatic tachycardia syndrome (POTS), in PASC participants. The interventions tested will include non-pharmacologic care and pharmacologic therapies with study drugs. Type: Interventional Start Date: Mar 2024 |
Strategies and Treatments for Respiratory Infections &Amp; Viral Emergencies (STRIVE): Immune Modulation...
University of Minnesota
COVID-19
COVID-19 can trigger a dysregulated immune response, and previous studies have shown that
immune modulation can improve outcomes in hospitalized patients. This trial is designed to
determine whether intensification of immune modulation early in the course of the disease
(while... expand
COVID-19 can trigger a dysregulated immune response, and previous studies have shown that immune modulation can improve outcomes in hospitalized patients. This trial is designed to determine whether intensification of immune modulation early in the course of the disease (while patients are on low flow oxygen) with abatacept (active arm) combined with standard of care (SOC) improves recovery as compared with placebo + SOC (placebo arm). For both groups, intensification of immunomodulation will be provided as part of SOC in case of signs of disease progression (patient requires high flow nasal oxygen (HFNO) or more support) and/or if the patient has rapidly increasing oxygen requirement. Type: Interventional Start Date: Jul 2023 |
Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study: Study Understanding...
AstraZeneca
COVID-19, SARS-CoV-2
AZD3152, a single mAb, is being developed to have broad neutralizing activity across known
SARS-CoV-2 variants of concern for pre-exposure prophylaxis of COVID-19.
The aim of the Phase I/III study (Parent Study) will be to evaluate the safety, efficacy and
neutralizing activity... expand
AZD3152, a single mAb, is being developed to have broad neutralizing activity across known SARS-CoV-2 variants of concern for pre-exposure prophylaxis of COVID-19. The aim of the Phase I/III study (Parent Study) will be to evaluate the safety, efficacy and neutralizing activity of AZD3152 compared with comparator for pre exposure prophylaxis of COVID-19, and separately evaluate the safety and PK of AZD5156, a combination of AZD3152 and AZD1061. Sub-study: This Phase II sub-study of SUPERNOVA will assess the safety, PK, and predicted neutralizing activity of AZD3152 compared with EVUSHELD for pre-exposure prophylaxis of COVID-19. Type: Interventional Start Date: Dec 2022 |
COVID Protection After Transplant - Sanofi GSK (CPAT-SG) Study
National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
Kidney Transplant
An open label, non-randomized pilot study in kidney transplant recipients who received a
completed primary series and bivalent booster of mRNA based COVID-19 vaccine and have =<2500
U/mL SARS-CoV-2 S antibody concentration using the Roche Elecsys(R) anti-RBD assay. Up to 80... expand
An open label, non-randomized pilot study in kidney transplant recipients who received a completed primary series and bivalent booster of mRNA based COVID-19 vaccine and have =<2500 U/mL SARS-CoV-2 S antibody concentration using the Roche Elecsys(R) anti-RBD assay. Up to 80 participants will be enrolled in this study. Eligible participants will receive a dose of the Sanofi-GSK monovalent (B.1.351) CoV2 preS dTM-AS03 COVID-19 vaccine candidate.. The primary objective is to determine whether a booster dose of the Sanofi-GSK monovalent (B.1.351) CoV2 preS dTM-AS03 COVID-19 vaccine will elicit an increased SARS-CoV-2 antibody response in participants who have failed to maintain an antibody titer >2500 U/mL (using the Roche Elecsys(R) anti-RBD assay) to 2 or more doses of mRNA based COVID-19 vaccine Type: Interventional Start Date: Feb 2023 |
A Study to Learn About New COVID-19 RNA Vaccine Candidates in COVID-19 Vaccine-Experienced Healthy Individuals
BioNTech SE
SARS-CoV-2 Infection
COVID-19
The purpose of this clinical trial is to learn about the safety, tolerability and
immunogenicity of BNT162b RNA-based SARS-CoV-2 vaccine candidates in adults to prevent
COVID-19.
For all cohorts (groups of participants), this study is seeking participants who are healthy... expand
The purpose of this clinical trial is to learn about the safety, tolerability and immunogenicity of BNT162b RNA-based SARS-CoV-2 vaccine candidates in adults to prevent COVID-19. For all cohorts (groups of participants), this study is seeking participants who are healthy (who may have preexisting disease if it is stable); All participants will receive a single dose of the study vaccine at the first study clinic and will return to the study clinic at least 4 more times. At each clinic visit, a blood sample will be taken. The study is about 6 months long for each participant. The vaccine candidates in this study are investigational but are very similar to BNT162b2 (Comirnaty), a COVID-19 RNA vaccine approved for use in the US and in many countries. For Cohort 1, this study included participants who were: - 18 through 55 years of age - have received 1 booster dose of a US-authorized COVID-19 vaccine, with the last dose being 90 or more days before Visit 1 of this study. All participants in Cohort 1 will receive 1 of the 2 study vaccines at a 30 microgram dose: BNT162b5 Bivalent (WT/OMI BA.2) or BNT162b2 Bivalent (WT/OMI BA.1). For Cohort 2, this study included participants who were: - 12 years of age and older - have received 3 prior doses of 30 micrograms BNT162b2, with the last dose being 150 to 365 days before Visit 1 of this study. Participants 12 through 17 years of age will receive BNT162b2 Bivalent (WT/OMI BA.4/BA.5) 30 micrograms. Participants 18 years and older will receive BNT162b2 Bivalent (WT/OMI BA.4/BA.5) at either a 30 microgram or a 60 microgram dose. For Cohort 3, this study included participants who were: - 18 years of age and older - have received 3 prior doses of 30 micrograms BNT162b2, with the last dose being 150 to 365 days before Visit 1 of this study. - Participants will receive BNT162b2 Bivalent (WT/OMI BA.4/BA.5) 30 micrograms. For Cohort 4, this study is seeking participants who are: - 18 through 55 years of age - have received 3 or 4 prior doses of a US-authorized mRNA COVID-19 vaccine (and dose level), with the last dose being a US-authorized BA.4/BA.5-adapted bivalent vaccine and dose level at least 150 days before Visit 1 of this study. All participants in Cohort 4 will receive 1 of the 5 study vaccines at a 30 microgram dose: BNT162b2 Bivalent (Original/ OMI BA.4/BA.5), BNT162b5 Bivalent (Original/OMI BA.4/BA.5), BNT162b6 Bivalent (Original/OMI BA.4/BA.5), BNT162b7 Bivalent (Original/OMI BA.4/BA.5) or BNT162b7 Monovalent (OMI BA.4/BA.5). Type: Interventional Start Date: Jul 2022 |
Reparixin add-on Therapy to Std Care to Limit Progression in Pts With COVID19 & Other Community Acquired...
Dompé Farmaceutici S.p.A
Infectious Pneumonia
Severe COVID-19
Primary objective:
- To evaluate the efficacy of oral reparixin versus standard care alone in limiting disease
progression in adult patients hospitalised for infectious pneumonia acquired in the community
(CAP), including COVID-19.
Secondary objectives:... expand
Primary objective: - To evaluate the efficacy of oral reparixin versus standard care alone in limiting disease progression in adult patients hospitalised for infectious pneumonia acquired in the community (CAP), including COVID-19. Secondary objectives: - To determine the effect of reparixin on several disease severity/progression measures including recovery, ventilatory free days and mortality. Safety objectives: - To evaluate the safety of oral reparixin versus placebo in the specific clinical setting. Type: Interventional Start Date: Apr 2022 |
Efficacy of Gabapentin for Post-Covid-19 Olfactory Dysfunction
Washington University School of Medicine
COVID-19
Olfactory Disorder
Anosmia
Hyposmia
Parosmia
This study will investigate the efficacy of oral gabapentin in olfactory improvement
following Covid-19- associated olfactory dysfunction. This is a randomized, double-blinded,
placebo-controlled trial.
expand
This study will investigate the efficacy of oral gabapentin in olfactory improvement following Covid-19- associated olfactory dysfunction. This is a randomized, double-blinded, placebo-controlled trial. Type: Interventional Start Date: Jan 2022 |
Randomized Double-Blind Phase 2 Study of Allogeneic HB-adMSCs for the Treatment of Chronic Post-COVID-19...
Hope Biosciences Stem Cell Research Foundation
Post COVID-19 Syndrome
This study will enroll up to 80 subjects with Chronic Post COVID-19 Syndrome. Subjects will
receive four intravenous injections of either allogeneic HB-adMSC's or a placebo over 10
weeks with two follow-up visits and an end of study visit at week 26.
expand
This study will enroll up to 80 subjects with Chronic Post COVID-19 Syndrome. Subjects will receive four intravenous injections of either allogeneic HB-adMSC's or a placebo over 10 weeks with two follow-up visits and an end of study visit at week 26. Type: Interventional Start Date: Jan 2022 |
Patients' Attitudes Toward and Experiences With Buprenorphine Treatment
Cambridge Health Alliance
Opioid-use Disorder
Acceptability of Health Care
Opioid-Related Disorders
This study will disseminate five surveys collecting individual's attitudes and experiences
during buprenorphine treatment for Opioid Use Disorder during the COVID-19 pandemic.
expand
This study will disseminate five surveys collecting individual's attitudes and experiences during buprenorphine treatment for Opioid Use Disorder during the COVID-19 pandemic. Type: Observational Start Date: Nov 2021 |
SARS-CoV-2 Donor-Recipient Immunity Transfer
City of Hope Medical Center
Accelerated Phase CML, BCR-ABL1 Positive
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
Chronic Phase CML, BCR-ABL1 Positive
This study investigates whether donors with previous exposure to COVID-19 can pass their
immunity by hematopoietic (blood) stem cell transplant (HCT) donation to patients that have
not been exposed. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus... expand
This study investigates whether donors with previous exposure to COVID-19 can pass their immunity by hematopoietic (blood) stem cell transplant (HCT) donation to patients that have not been exposed. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus that causes the COVID19 infection. This study may provide critical information for medical decision-making and possible immunotherapy interventions in immunocompromised transplant recipients, who are at high risk for COVID19 severe illness. Type: Observational Start Date: Sep 2020 |
Remotely Delivered Programs Targeting COVID-19 Stress-Related Depression and Substance Use
Cambridge Health Alliance
Depression
Anxiety
Substance Use
Stress, Psychological
Stress, Emotional
This 3-arm study compares the effectiveness of an (1) 8-week mindfulness-based intervention,
MBCT-R (Mindfulness-Based Cognitive Therapy for Resilience During COVID-19)+CHA MindWell vs.
(2) iCBT (internet based Cognitive Behavioral Therapy)+ CHA MindWell vs. (3) CHA MindWell... expand
This 3-arm study compares the effectiveness of an (1) 8-week mindfulness-based intervention, MBCT-R (Mindfulness-Based Cognitive Therapy for Resilience During COVID-19)+CHA MindWell vs. (2) iCBT (internet based Cognitive Behavioral Therapy)+ CHA MindWell vs. (3) CHA MindWell remote monitoring and telephone coaching alone on depressive symptoms as measured over the course of 24-weeks by the computerized adaptive mental health (CAT-MH) interview for depression (CAT-DI). Secondary outcomes include rates and levels of alcohol and drug use, as well as the number of required mental health clinician visits (televisits and in-person visits). Exploratory outcomes include stress-related affect reactivity and salivary inflammatory markers (e.g., interleukin-6). Type: Interventional Start Date: Mar 2021 |
Understanding Immunity to the Flu Vaccine in COVID-19 Patients
Stanford University
Corona Virus Infection
Flu Vaccine
Immunity
The purpose of this study is to measure immunity to the flu vaccine over time in patients who
had COVID-19. Adults who have been diagnosed with COVID-19 as well as controls without
COVID-19 will be invited to participate in this study.
expand
The purpose of this study is to measure immunity to the flu vaccine over time in patients who had COVID-19. Adults who have been diagnosed with COVID-19 as well as controls without COVID-19 will be invited to participate in this study. Type: Observational Start Date: Oct 2020 |
Umbilical Cord Lining Stem Cells (ULSC) in Patients With COVID-19 ARDS
Restem, LLC.
Covid19
Corona Virus Infection
SARS-CoV Infection
ARDS
Coronavirus
ULSC-CV-01 is a clinical trial that comprises both Phase 1 and Phase 2a, which will be
conducted sequentially. This trial will evaluate the safety and potential efficacy of
allogeneic Umbilical Cord Lining Stem Cells (ULSC), which are a type of umbilical cord tissue
derived... expand
ULSC-CV-01 is a clinical trial that comprises both Phase 1 and Phase 2a, which will be conducted sequentially. This trial will evaluate the safety and potential efficacy of allogeneic Umbilical Cord Lining Stem Cells (ULSC), which are a type of umbilical cord tissue derived mesenchymal stem cells (MSC), with intravenous (IV) administration in hospitalized patients with acute respiratory distress syndrome (ARDS) due to COVID-19. Type: Interventional Start Date: Dec 2020 |
Breathing Techniques and Meditation for Health Care Workers During COVID-19 Pandemic
M.D. Anderson Cancer Center
COVID-19 Infection
This phase I trial investigates breathing techniques and meditation for health care workers
during COVID-19 pandemic. Breathing techniques and medication may help manage stress and
improve lung health. The goal of this trial is to learn if breathing techniques and
meditation... expand
This phase I trial investigates breathing techniques and meditation for health care workers during COVID-19 pandemic. Breathing techniques and medication may help manage stress and improve lung health. The goal of this trial is to learn if breathing techniques and meditation may help to reduce stress and improve lung health in health care workers during the COVID-19 pandemic. Type: Interventional Start Date: Jun 2020 |
Effect of Lactobacillus on the Microbiome of Household Contacts Exposed to COVID-19
Duke University
Microbiome
The purpose of this study is to evaluate the effect of the probiotic Lactobacillus rhamnosus
GG (LGG) and the effect of COVID-19 on the microbiome (the microorganisms that live in and on
the human body) in exposed household contacts of COVID-19. This is a randomized,
double-blind,... expand
The purpose of this study is to evaluate the effect of the probiotic Lactobacillus rhamnosus GG (LGG) and the effect of COVID-19 on the microbiome (the microorganisms that live in and on the human body) in exposed household contacts of COVID-19. This is a randomized, double-blind, placebo-controlled study, meaning subjects will be randomly assigned to receive LGG or a placebo (an inactive substance given in the same form as the active substance) and will not know which product they are receiving. Subjects will participate in the study for around 60 days. All subjects must refrain from taking any other probiotics while on study. All subjects must have access to e-mail and the internet to complete study questionnaires. Participation in this study entails taking LGG/placebo for 28 days, responding to questionnaires, and providing stool and nasal swab samples. Type: Interventional Start Date: Jun 2020 |
Longitudinal Innate Immunity and Aging Study
University of Colorado, Denver
Healthy Older Adults Ages 60-89
This study plans to examine biological bases of cognitive aging. The goals of the study are
to better understand how immune system markers, measured in the blood and in the spinal
fluid, are related to clinical features of aging over time. The study also aims to better
understand... expand
This study plans to examine biological bases of cognitive aging. The goals of the study are to better understand how immune system markers, measured in the blood and in the spinal fluid, are related to clinical features of aging over time. The study also aims to better understand how different types of biomarkers may relate to immune health and the aging process. This research may ultimately help us better understand what puts individuals at risk for cognitive decline and for Alzheimer's disease. Type: Observational Start Date: Apr 2019 |
Valacyclovir Plus Celecoxib for Post-Acute Sequelae of SARS-CoV-2
Bateman Horne Center
Long COVID
PASC Post Acute Sequelae of COVID 19
To explore the safety and efficacy of daily doses of celecoxib + valacyclovir in the
treatment of patients with prolonged symptoms caused by COVID-19.
expand
To explore the safety and efficacy of daily doses of celecoxib + valacyclovir in the treatment of patients with prolonged symptoms caused by COVID-19. Type: Interventional Start Date: Oct 2023 |
Predictors of Post-COVID Clinical and Cognitive Consequences
VA Office of Research and Development
Post Acute Sequelae of SARS CoV 2 Infection
Obstructive Sleep Apnea
The CDC describes Post-acute sequelae of SARS-COV-2 infection (PASC) for the wide range of
physical and mental health consequences experienced by some patients. These sequelae may be
present four or more weeks after SARS-COV-2 infection, including patients who had initial... expand
The CDC describes Post-acute sequelae of SARS-COV-2 infection (PASC) for the wide range of physical and mental health consequences experienced by some patients. These sequelae may be present four or more weeks after SARS-COV-2 infection, including patients who had initial mild or asymptomatic acute infection. However, there is complete absence of data whether chronic sleep changes due to COVID-19 infection may influence these physical and mental health consequences. While fatigue is one of the common post-COVID conditions, there are no systematic examinations of sleep disturbances in COVID-19 survivors. This will be a pilot observational retrospective and prospective cohort study, to systematically assess if sleep disturbances and severity of sleep apnea comprise a modifiable facet of PASC as well as the short-term and longer-term effects of COVID-19 infection itself on sleep, cognitive function, exercise capacity and lung function. Type: Observational [Patient Registry] Start Date: Jan 2023 |
SGB for COVID-induced Parosmia
Washington University School of Medicine
COVID-19-Induced Parosmia
Chronic olfactory dysfunction, both hyposmia and parosmia, from the COVID-19 pandemic is a
growing public health crisis with up to 1.2 million people in the United States affected.
Olfactory dysfunction impacts one's quality of life significantly by decreasing the enjoyment... expand
Chronic olfactory dysfunction, both hyposmia and parosmia, from the COVID-19 pandemic is a growing public health crisis with up to 1.2 million people in the United States affected. Olfactory dysfunction impacts one's quality of life significantly by decreasing the enjoyment of foods, creating environmental safety concerns, and affecting one's ability to perform certain jobs. Olfactory loss is also an independent predictor of anxiety, depression, and even mortality. Recent research by our group (unpublished data) and suggests that parosmias, moreso than hyposmias, can result in increased rates of anxiety, depression, and even suicidal ideation. While the pandemic has increased the interest by the scientific community in combating the burgeoning health crisis, few effective treatments currently exist for olfactory dysfunction. Persistent symptoms after an acute COVID-19 infection, or "Long COVID" symptoms, have been hypothesized to be a result of sympathetic positive feedback loops and dysautonomia. Stellate ganglion blocks have been proposed to treat this hyper-sympathetic activation by blocking the sympathetic neuronal firing and resetting the balance of the autonomic nervous system. Studies prior to the COVID-19 pandemic have supported a beneficial effect of stellate ganglion blocks on olfactory dysfunction, and recent news reports and a published case series have described a dramatic benefit in both olfactory function and other long COVID symptoms in patients receiving stellate ganglion blocks. A previous pilot study using stellate ganglion blocks of 20 participants with persistent COVID-19 olfactory dysfunction resulted modest improvements in subjective olfactory function, smell identification, and olfactory-specific quality-of-life, but it lacked a control group. Therefore, we propose a double-blinded, placebo-controlled randomized clinical trial assessing the efficacy of a stellate ganglion block versus saline injection in a total of up to 140 participants with persistent COVID-19-associated olfactory dysfunction. Type: Interventional Start Date: Oct 2023 |
Post-marketing Safety of Elasomeran/Davesomeran and Andusomeran
ModernaTX, Inc.
SARS-CoV-2
The main objective of the study is to evaluate the safety of the elasomeran/davesomeran and
andusomeran vaccines as used in routine clinical practice.
expand
The main objective of the study is to evaluate the safety of the elasomeran/davesomeran and andusomeran vaccines as used in routine clinical practice. Type: Observational Start Date: Apr 2023 |
A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals
BioNTech SE
SARS-CoV-2 Infection
COVID-19
The purpose of this clinical protocol is to learn about the safety, tolerability, and
immunogenicity of new BNT162b2 RNA-based vaccine candidates targeting new variants of
SARS-CoV-2 in healthy people.
Substudy A:
- This study will evaluate the safety, tolerability,... expand
The purpose of this clinical protocol is to learn about the safety, tolerability, and immunogenicity of new BNT162b2 RNA-based vaccine candidates targeting new variants of SARS-CoV-2 in healthy people. Substudy A: - This study will evaluate the safety, tolerability, and immunogenicity of BNT162b2 (Omi XBB.1.5) given as a single 30 µg dose, - in people who are 12 years of age and older, - who previously received at least 3 doses of a US-authorized mRNA COVID-19 vaccine, with the most recent dose being an Omicron BA.4/BA.5-adapted bivalent vaccine received at least 150 days before the study vaccination (Visit 1). - The study is about 6 months long for each participant. - Participants will have at least 5 visits to the clinic. - At each clinic visit a blood sample will be taken. - At least 1 nasal swab will taken. Substudy B: - This study will evaluate the safety, tolerability, and immunogenicity of BNT162b2 (Omi XBB.1.5) given as a single 30 µg dose, - in people who are 12 years of age and older, - who are COVID-19 vaccine-naïve - who have had any positive SARS-CoV-2 test result >28 days before study vaccine administration. - The study is about 6 months long for each participant. - Participants will have at least 5 visits to the clinic. - At each clinic visit a blood sample will be taken. - At least 1 nasal swab will taken. Type: Interventional Start Date: Aug 2023 |
Study of Obeldesivir in Children and Adolescents With COVID-19
Gilead Sciences
COVID-19
The goal of this clinical study is to learn more about the safety and tolerability of
obeldesivir (ODV) in children and adolescents with coronavirus disease 2019 (COVID-19).
The primary objectives are to evaluate the plasma pharmacokinetics (PK), safety and
tolerability... expand
The goal of this clinical study is to learn more about the safety and tolerability of obeldesivir (ODV) in children and adolescents with coronavirus disease 2019 (COVID-19). The primary objectives are to evaluate the plasma pharmacokinetics (PK), safety and tolerability of ODV in pediatric participants with COVID-19. Type: Interventional Start Date: Dec 2023 |
A Safety and Immune Response Study to Evaluate Varying Doses of an mRNA Vaccine Against Coronavirus Disease...
GlaxoSmithKline
COVID-19
The purpose of this study is to evaluate the safety, reactogenicity and immune responses of
the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA-CR-04 vaccine construct
when administered in healthy adults previously vaccinated with SARS-CoV-2 mRNA vaccines.... expand
The purpose of this study is to evaluate the safety, reactogenicity and immune responses of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA-CR-04 vaccine construct when administered in healthy adults previously vaccinated with SARS-CoV-2 mRNA vaccines. Type: Interventional Start Date: Aug 2023 |
Sauna for Long Covid
Massachusetts General Hospital
Long COVID
Research suggests that Whole Body Hyperthermia in a sauna-like environment can reduce
symptoms related to post-acute sequelae of SARS-CoV-2 (PASC), or Long Covid. The
investigators aim to study the feasibility and treatment effect of this procedure for
patients experiencing... expand
Research suggests that Whole Body Hyperthermia in a sauna-like environment can reduce symptoms related to post-acute sequelae of SARS-CoV-2 (PASC), or Long Covid. The investigators aim to study the feasibility and treatment effect of this procedure for patients experiencing Long Covid symptoms. Type: Interventional Start Date: May 2024 |
- Previous
- Next